These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20455595)
21. Age distribution patterns of patients with conventional ductal adenocarcinoma of the pancreas. A single-institution study of 580 cases re-evaluated using current histopathological diagnostic criteria. Liszka Ł; Pająk J; Mrowiec S; Zielińska-Pająk E; Lampe P; Gołka D Pol J Pathol; 2010; 61(2):65-77. PubMed ID: 20924989 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of MSX2 mRNA in brush cytology specimens distinguished pancreatic carcinoma from chronic pancreatitis. Satoh K; Hamada S; Kanno A; Ishida K; Ito H; Hirota M; Masamune A; Egawa S; Unno M; Shimosegawa T Cancer Sci; 2011 Jan; 102(1):157-61. PubMed ID: 20961362 [TBL] [Abstract][Full Text] [Related]
23. Localization of the human hedgehog-interacting protein (Hip) in the normal and diseased pancreas. Kayed H; Kleeff J; Esposito I; Giese T; Keleg S; Giese N; Büchler MW; Friess H Mol Carcinog; 2005 Apr; 42(4):183-92. PubMed ID: 15754313 [TBL] [Abstract][Full Text] [Related]
25. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Shih NY; Lai HL; Chang GC; Lin HC; Wu YC; Liu JM; Liu KJ; Tseng SW Jpn J Clin Oncol; 2010 Jul; 40(7):663-9. PubMed ID: 20395242 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Cai SW; Yang SZ; Gao J; Pan K; Chen JY; Wang YL; Wei LX; Dong JH Surgery; 2011 Apr; 149(4):576-84. PubMed ID: 21167541 [TBL] [Abstract][Full Text] [Related]
27. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Mardin WA; Mees ST Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633 [TBL] [Abstract][Full Text] [Related]
28. Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Maruyama I; Ohguro H; Ikeda Y Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1657-65. PubMed ID: 10845582 [TBL] [Abstract][Full Text] [Related]
29. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. Yoneda M; Fujii A; Ito A; Yokoyama H; Nakagawa H; Kuriyama M J Neuroimmunol; 2007 Apr; 185(1-2):195-200. PubMed ID: 17335908 [TBL] [Abstract][Full Text] [Related]
30. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
31. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Erkan M; Michalski CW; Rieder S; Reiser-Erkan C; Abiatari I; Kolb A; Giese NA; Esposito I; Friess H; Kleeff J Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1155-61. PubMed ID: 18639493 [TBL] [Abstract][Full Text] [Related]
32. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308 [TBL] [Abstract][Full Text] [Related]
33. Serum EpCAM expression in pancreatic cancer. Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052 [TBL] [Abstract][Full Text] [Related]
34. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339 [TBL] [Abstract][Full Text] [Related]
35. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival. Curcio C; Rosso T; Brugiapaglia S; Guadagnin G; Giordano D; Castellino B; Satolli MA; Spadi R; Campra D; Moro F; Papotti MG; Bertero L; Cassoni P; De Angelis C; Langella S; Ferrero A; Armentano S; Bellotti G; Fenocchio E; Nuzzo A; Ciccone G; Novelli F Clin Exp Med; 2023 Dec; 23(8):5089-5100. PubMed ID: 37910256 [TBL] [Abstract][Full Text] [Related]
36. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484 [TBL] [Abstract][Full Text] [Related]
37. α-Enolase: a promising therapeutic and diagnostic tumor target. Capello M; Ferri-Borgogno S; Cappello P; Novelli F FEBS J; 2011 Apr; 278(7):1064-74. PubMed ID: 21261815 [TBL] [Abstract][Full Text] [Related]
38. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952 [TBL] [Abstract][Full Text] [Related]